{SNA} Agonists, Approved Therapeutics/Drug Candidates, Biochemicals and Reagents, Boehringer Ingelheim, Cell Biology, Cell Signaling and Neuroscience, Dopaminergics,
相关文献及参考
[2]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71.
[3]. Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961.
[4]. P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28.
[5]. Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860.
[1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.
[1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.